胃癌分子診斷市場規模、佔有率和成長分析（按檢測類型、生物標記、應用、最終用戶和地區分類）：產業預測（2026-2033 年）

2024 年全球胃癌分子診斷市場價值為 31 億美元，預計到 2025 年將成長至 34.8 億美元，到 2033 年將成長至 87.4 億美元，預測期（2026-2033 年）複合年成長率為 12.2%。

全球胃癌分子診斷市場由用於識別基因突變、表觀遺傳修飾和蛋白質生物標記的創新技術所驅動，這些技術對於開發胃癌個人化治療方案至關重要。精準腫瘤學的日益普及源於改善患者預後和降低治療相關毒性的需求。市場正從簡單的HER2檢測發展到針對多種治療相關突變的次世代定序panel，加速其融入臨床工作流程和啟動治療，尤其是在亞洲和歐洲。不斷擴大的保險報銷政策促進了基於基因分型療法的應用，推動了市場成長，而新興市場胃癌發病率的上升凸顯了對早期檢測解決方案的需求。這些趨勢正在促進診斷公司和製藥公司之間的策略合作，進一步提升了整體市場潛力。

全球胃癌分子診斷市場促進因素

醫療專業人員對精準分子診斷的需求日益成長，以指導標靶治療的選擇，這推動了個人化治療方案需求的顯著提升，並顯著影響全球胃癌分子診斷市場。詳細的腫瘤分析能夠識別特定的基因突變，從而最佳化治療方案的製定，改善患者預後，並最大限度地降低無效治療的風險。這項轉變促使醫療機構和腫瘤專科中心優先採用先進的診斷工具，製造商也正在加速產品線的拓展和技術創新。因此，臨床認可度和患者信心顯著提高，從而推動了整體市場的成長。

全球胃癌分子診斷市場面臨的限制因素

分子診斷檢測的高昂成本是其廣泛應用的一大障礙，尤其是在醫療資源匱乏的醫療系統和發展中地區。由於需要複雜的試劑、專用設備和熟練的專業人員，分子診斷檢測的成本顯著增加，限制了經濟困難的患者和醫療機構的負擔。因此，醫療服務提供者可能選擇依賴準確性較低的傳統診斷技術，而保險公司也可能設定報銷限制，從而阻礙市場擴張並降低診斷公司的潛在獲利能力。此外，缺乏經濟有效的定價策略也阻礙了小規模實驗室投資最尖端科技，進一步抑制了市場成長。

胃癌分子診斷的全球市場趨勢

在全球胃癌分子診斷市場，一個重要趨勢正在興起：將精準基因組分析整合到標準治療方案中。這項進步使醫療服務提供者能夠進行全面的基因組分析，從而幫助識別具有治療意義的突變並制定標靶治療。隨著定序技術的進步和分子層面資訊可靠性的提高，這些診斷方法在各大癌症中心的應用範圍不斷擴大。這種轉變正在改變我們的臨床實踐方式，醫生們越來越重視早期分子檢測，從而改善治療效果，並制定個人化的護理策略，以加強患者在整個疾病過程中的管理和監測。

目錄

介紹

• 分析目的
• 市場定義和範圍

分析方法

• 分析過程
• 二級資料和一級資料的方法
• 估算市場規模的方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態與展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特五力分析及其影響
  • 競爭公司之間的競爭
  • 替代品的威脅
  • 買方的議價能力
  • 新進入者的威脅
  • 供應商的議價能力

關鍵市場觀察

• 主要成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 市場魅力指數（2025）
• PESTLE分析
• 監理情勢

全球胃癌分子診斷市場規模：依檢測類型分類

• 分子生物標記檢測
• 基於PCR的檢測
• 次世代定序檢測
• 液態生物檢體
• 其他

全球胃癌分子診斷市場規模：依生物標記分類

• HER2
• PD-L1
• 微衛星不穩定性
• EB病毒
• 其他

全球胃癌分子診斷市場規模：依應用領域分類

• 診斷
• 治療方案
• 預後
• 疾病監測

全球胃癌分子診斷市場規模：依最終用戶分類

• 醫院
• 診斷檢查室
• 研究機構
• 其他

全球胃癌分子診斷市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭格局

• 前五大公司對比
• 主要公司的市場定位（2025 年）
• 主要公司採取的策略
• 近期市場趨勢
• 主要公司市佔率（2025 年）
• 主要公司簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 2023-2025年營收年比比較

主要公司簡介

• F. Hoffmann-La Roche Ltd
• Abbott Laboratories
• QIAGEN NV
• Thermo Fisher Scientific Inc.
• Danaher Corporation
• Illumina, Inc.
• Bio-Rad Laboratories, Inc.
• Agilent Technologies, Inc.
• DiaSorin SpA
• Hologic, Inc.
• Guardant Health, Inc.
• Foundation Medicine, Inc.
• Natera, Inc.
• Exact Sciences Corporation
• Myriad Genetics, Inc.
• Genomic Health
• Burning Rock Biotech Limited
• BGI Genomics Co., Ltd.
• Amoy Diagnostics Co., Ltd.
• Singlera Genomics Inc.

結論與建議

Global Stomach Cancer Molecular Diagnostics Market size was valued at USD 3.1 Billion in 2024 and is poised to grow from USD 3.48 Billion in 2025 to USD 8.74 Billion by 2033, growing at a CAGR of 12.2% during the forecast period (2026-2033).

The global market for stomach cancer molecular diagnostics is driven by innovative technologies used to identify genetic mutations, epigenetic modifications, and protein biomarkers, essential for tailoring personalized therapies in gastric cancer treatment. The increasing focus on precision oncology stem from the need for improved patient outcomes and decreased treatment-related toxicity. The market evolution from simple HER2 testing to advanced next-generation sequencing panels that target multiple actionable variants has gained traction, particularly in Asia and Europe, where integration into clinical workflows has accelerated treatment initiation. Expanding reimbursement policies foster market growth by endorsing genotype-guided therapies, while rising gastric cancer prevalence in emerging markets highlights the demand for early detection solutions. These trends are fueling strategic collaborations between diagnostic and pharmaceutical companies, enhancing overall market potential.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Stomach Cancer Molecular Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Stomach Cancer Molecular Diagnostics Market Segments Analysis

Global stomach cancer molecular diagnostics market is segmented by test type, biomarker, application, end user and region. Based on test type, the market is segmented into Molecular Biomarker Tests, PCR-Based Tests, Next-Generation Sequencing Tests, Liquid Biopsy Tests and Others. Based on biomarker, the market is segmented into HER2, PD-L1, Microsatellite Instability, Epstein-Barr Virus and Others. Based on application, the market is segmented into Diagnosis, Treatment Selection, Prognosis and Disease Monitoring. Based on end user, the market is segmented into Hospitals, Diagnostic Laboratories, Research Institutions and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Stomach Cancer Molecular Diagnostics Market

The rising demand for personalized treatment approaches is significantly influencing the Global Stomach Cancer Molecular Diagnostics market, as healthcare professionals seek accurate molecular diagnostics to guide targeted therapy selection. Detailed tumor profiling allows for the identification of specific genetic alterations, thereby enhancing treatment planning and improving patient outcomes while minimizing the risk of ineffective therapies. This shift leads healthcare providers and oncology facilities to prioritize the adoption of sophisticated diagnostic tools, encouraging manufacturers to broaden their product offerings and innovate more rapidly. As a result, there is a notable increase in clinical acceptance and patient confidence, driving overall market growth.

Restraints in the Global Stomach Cancer Molecular Diagnostics Market

The high expense associated with molecular diagnostic tests represents a notable obstacle to their extensive adoption, especially within resource-limited healthcare systems and developing regions. The costs linked to sophisticated reagents, specialized equipment, and the necessity for trained professionals significantly elevate overall expenses, restricting access for patients and institutions operating under financial constraints. As a result, healthcare providers may choose to rely on traditional diagnostic techniques that are less accurate, and insurers might impose reimbursement limitations, hindering market expansion and limiting revenue potential for diagnostic companies. Moreover, the absence of cost-effective pricing strategies deters smaller laboratories from investing in cutting-edge technologies, further impeding market growth.

Market Trends of the Global Stomach Cancer Molecular Diagnostics Market

The Global Stomach Cancer Molecular Diagnostics market is witnessing a significant trend toward the integration of precision genomics into standard care protocols. This evolution allows healthcare providers to implement comprehensive genomic profiling, which aids in the identification of actionable mutations and the tailoring of targeted therapies. As advancements in sequencing technologies enhance the reliability of molecular insights, the adoption of these diagnostics is expanding across oncology centers. This shift is reshaping clinical practices, as physicians increasingly prioritize early molecular testing, leading to improved treatment outcomes and personalized care strategies that enhance patient management and monitoring throughout the disease trajectory.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porter's Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitutes
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Stomach Cancer Molecular Diagnostics Market Size by Test Type & CAGR (2026-2033)

• Market Overview
• Molecular Biomarker Tests
• PCR-Based Tests
• Next-Generation Sequencing Tests
• Liquid Biopsy Tests
• Others

Global Stomach Cancer Molecular Diagnostics Market Size by Biomarker & CAGR (2026-2033)

• Market Overview
• HER2
• PD-L1
• Microsatellite Instability
• Epstein-Barr Virus
• Others

Global Stomach Cancer Molecular Diagnostics Market Size by Application & CAGR (2026-2033)

• Market Overview
• Diagnosis
• Treatment Selection
• Prognosis
• Disease Monitoring

Global Stomach Cancer Molecular Diagnostics Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Diagnostic Laboratories
• Research Institutions
• Others

Global Stomach Cancer Molecular Diagnostics Market Size & CAGR (2026-2033)

• North America (Test Type, Biomarker, Application, End User)
  • US
  • Canada
• Europe (Test Type, Biomarker, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Test Type, Biomarker, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Test Type, Biomarker, Application, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Test Type, Biomarker, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DiaSorin S.p.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guardant Health, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Foundation Medicine, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Natera, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exact Sciences Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genomic Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Burning Rock Biotech Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BGI Genomics Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amoy Diagnostics Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Singlera Genomics Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations